70c imo is a key metric .. going all the way back (imo)

New Post Public Reply Private Reply Replies (1) Message Board
4kids zdubble17 #68420
688
70c imo is a key metric .. going all the way back (imo)
to when NR first targeted CTIX (from memory so i may
be off slightly) .. NR worked cycles of money on CTIX from
9/2012 to EO 2014 before what i refer to as the *handoff* from
NRs' .. cycles of money .. re: controlled take up/s to the take down

and 70c was also key again several years ago after a few
years of NR relentlessly compressing CTIX/IPIX .. (again
from memory so i'd need to check .. but i believe that was
early 2018) .. and 2018 was beyond revealing for a few reasons

in 2018 .. IPIX did approx 33M~ in volume for the first 8 months of the year
PPS in early September 2018 was 53c .. over the next 4 months .. NR would
brutalize IPIX .. on volume injection (approx 55M~) for a total YTD *volume*
of 88M~ (2018) .. and relentless PPS compression (resetting 52 week low)
to 7c (12.31.18) .. NR loves to work those EOY troll mantras of *tax loss* selling

i've suspected since C-19 *upended* NRs' *goals* re: IPIX .. that NR is walking
a very fine % ratio line .. and that NR needs to make IPIX a *trading* stock
which is easier said than accomplished after NRs' *imo* staggering *volume injection* just since 2018

not having a broker's license .. i offer no financial advice .. but i've always been a proponent of DCA'ing (dollar cost averaging) shares of those companies i invest in .. i'm odd that way .. i like even numbers for my investments ..

best wishes on what route you pursue

4kids
Quote:

4kids was the 70c area still in play according to your last post, just trying to see what to expect. Whether I buy more now or I look to buy more at a lower area?

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Hyzon Motors Plans Delisting from Nasdaq—What This Means

Updated Category News Views 195

Hyzon Motors Announces Delisting from Nasdaq Hyzon Motors Inc. is making a significant shift regarding its stock trading status. This U.S. company, known for its commitment to high-performance hydrogen fuel cell technology, has decided to inform Nasdaq Stock Market of its intent to delist its Class A common stock and publicly traded warrants. This move comes as part of...

Continue Reading
Unlock the Potential of Crypto Staking with Keynode.net

Updated Category News Views 113

Your Gateway to High Returns in Crypto Staking As the digital currency landscape continues to expand, platforms like Keynode.net are leading the charge in offering unprecedented opportunities for investors. For those seeking impressive annual percentage yields (APY) through crypto staking, Keynode.net has emerged as a premier choice. Its user-friendly interface, robust...

Continue Reading
Critical Updates for Rocket Pharmaceuticals Investors Amid Lawsuit

Updated Category News Views 263

Overview of the Class Action Lawsuit Against Rocket Pharmaceuticals Pomerantz LLP has initiated a class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) highlighting various concerns regarding the company's business practices. Investors who have suffered losses during the stipulated Class Period should take note of this unfolding situation. Key Details...

Continue Reading
Revitalizing Economic Growth at the 23rd SMDO Conference

Updated Category News Views 141

Revitalizing Economic Growth at the 23rd SMDO Conference The 23rd Annual South Metro Development Outlook (SMDO25) Conference stands as a pivotal forum for industry leaders, policymakers, and community stakeholders. It is designed to foster collaboration and tackle some of the most pressing issues faced by the region today. Set against the backdrop of changing federal...

Continue Reading
SciBase's Strong Growth in Q1 2025: Key Highlights and Future

Updated Category News Views 222

Strong First Quarter Results for SciBase In the recent interim report, SciBase has showcased an impressive performance for the first quarter of 2025. The medical technology company, renowned for its innovative dermatological solutions, recorded net sales of TSEK 8,856, marking a remarkable increase of 46% from the previous year’s figures. Financial Performance Overview...

Continue Reading